0YX Stock Overview
Engages in the development, manufacture, and sale of diagnostic instruments, reagents, and related software in Japan. More details
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 2/6 |
Past Performance | 5/6 |
Financial Health | 5/6 |
Dividends | 4/6 |
My Notes
Capture your thoughts, links and company narrative
Sysmex Corporation Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | JP¥17.40 |
52 Week High | JP¥20.40 |
52 Week Low | JP¥13.60 |
Beta | 0.63 |
1 Month Change | -8.42% |
3 Month Change | 1.75% |
1 Year Change | 2.35% |
3 Year Change | -55.38% |
5 Year Change | -14.43% |
Change since IPO | 55.79% |
Recent News & Updates
Recent updates
Shareholder Returns
0YX | DE Medical Equipment | DE Market | |
---|---|---|---|
7D | -2.2% | -2.9% | -2.6% |
1Y | 2.4% | -8.5% | 6.9% |
Return vs Industry: 0YX exceeded the German Medical Equipment industry which returned -8.5% over the past year.
Return vs Market: 0YX underperformed the German Market which returned 6.9% over the past year.
Price Volatility
0YX volatility | |
---|---|
0YX Average Weekly Movement | 7.1% |
Medical Equipment Industry Average Movement | 6.6% |
Market Average Movement | 4.8% |
10% most volatile stocks in DE Market | 11.2% |
10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 0YX's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 0YX's weekly volatility (7%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1968 | 10,042 | n/a | www.sysmex.co.jp |
Sysmex Corporation engages in the development, manufacture, and sale of diagnostic instruments, reagents, and related software in Japan. It offers three-part and five-part white blood cell differentiation instruments for use in hematology; and transport systems for high-volume testing in labs. The company also provides automated urine particle analyzers; automated blood coagulation analyzers; automated immunochemistry systems, which perform assays on minute sample quantities, as well as reagents to test for infectious disease and tumor markers; and flow cytometers to perform analysis in diagnosing leukemia, malignant lymphoma, and HIV/AIDS.
Sysmex Corporation Fundamentals Summary
0YX fundamental statistics | |
---|---|
Market cap | €11.14b |
Earnings (TTM) | €327.65m |
Revenue (TTM) | €3.01b |
34.0x
P/E Ratio3.7x
P/S RatioIs 0YX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
0YX income statement (TTM) | |
---|---|
Revenue | JP¥491.29b |
Cost of Revenue | JP¥228.51b |
Gross Profit | JP¥262.78b |
Other Expenses | JP¥209.32b |
Earnings | JP¥53.46b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 12, 2025
Earnings per share (EPS) | 85.73 |
Gross Margin | 53.49% |
Net Profit Margin | 10.88% |
Debt/Equity Ratio | 7.1% |
How did 0YX perform over the long term?
See historical performance and comparisonDividends
1.0%
Current Dividend Yield34%
Payout RatioDoes 0YX pay a reliable dividends?
See 0YX dividend history and benchmarksSysmex dividend dates | |
---|---|
Ex Dividend Date | Mar 28 2025 |
Dividend Pay Date | Jun 24 2025 |
Days until Ex dividend | 95 days |
Days until Dividend pay date | 183 days |
Does 0YX pay a reliable dividends?
See 0YX dividend history and benchmarksCompany Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2024/12/22 01:30 |
End of Day Share Price | 2024/12/20 00:00 |
Earnings | 2024/09/30 |
Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Sysmex Corporation is covered by 35 analysts. 16 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Yoshitsugu Sasaki | Aizawa Securities Co. Ltd. |
Masahiro Nakanomyo | Barclays |
Craig Nelson | BNP Paribas Securities (Asia) |